RU93050932A - MEANS FOR TREATMENT OF ATOPIC DERMATITIS - Google Patents

MEANS FOR TREATMENT OF ATOPIC DERMATITIS

Info

Publication number
RU93050932A
RU93050932A RU93050932/14A RU93050932A RU93050932A RU 93050932 A RU93050932 A RU 93050932A RU 93050932/14 A RU93050932/14 A RU 93050932/14A RU 93050932 A RU93050932 A RU 93050932A RU 93050932 A RU93050932 A RU 93050932A
Authority
RU
Russia
Prior art keywords
treatment
atopic dermatitis
actovegin
infusions
course
Prior art date
Application number
RU93050932/14A
Other languages
Russian (ru)
Other versions
RU2109513C1 (en
Inventor
М.М. Кохан
Н.В. Кунгуров
О.Е. Рамазанова
Original Assignee
Свердловский научно-исследовательский кожно-венерологический институт МЗ РФ
Filing date
Publication date
Application filed by Свердловский научно-исследовательский кожно-венерологический институт МЗ РФ filed Critical Свердловский научно-исследовательский кожно-венерологический институт МЗ РФ
Priority to RU93050932A priority Critical patent/RU2109513C1/en
Priority claimed from RU93050932A external-priority patent/RU2109513C1/en
Publication of RU93050932A publication Critical patent/RU93050932A/en
Application granted granted Critical
Publication of RU2109513C1 publication Critical patent/RU2109513C1/en

Links

Claims (1)

Изобретение относится к медицине, а именно к дерматологии, и касается средства для лечения атопического дерматита. Целью изобретения является применение инфузий известного лекарственного препарата актовегина в качестве средства для лечения атопического дерматита. Цель достигается тем, что пациенту внутривенно капельно вводят 14 мл актовегина для инъекций в 250,0 мл физиологического раствора со скоростью 40 капель в минуту. На курс лечения применяют 5 - 7 инфузий через день, разовая доза составляет 0,56 г, курсовая - 2,8 - 3,9 г активного вещества. Побочных явлений не установлено.The invention relates to medicine, namely to dermatology, and relates to agents for the treatment of atopic dermatitis. The aim of the invention is the use of infusions of the known drug Actovegin as a means for the treatment of atopic dermatitis. The goal is achieved by the fact that a patient is injected intravenously with 14 ml of Actovegin for injection in 250.0 ml of physiological saline at a rate of 40 drops per minute. For the course of treatment, 5 to 7 infusions are used every other day, a single dose is 0.56 g, the course dose is 2.8 - 3.9 g of the active substance. Side effects have not been established.
RU93050932A 1993-11-09 1993-11-09 Method to treat atopic dermatitis RU2109513C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU93050932A RU2109513C1 (en) 1993-11-09 1993-11-09 Method to treat atopic dermatitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU93050932A RU2109513C1 (en) 1993-11-09 1993-11-09 Method to treat atopic dermatitis

Publications (2)

Publication Number Publication Date
RU93050932A true RU93050932A (en) 1997-01-10
RU2109513C1 RU2109513C1 (en) 1998-04-27

Family

ID=20149004

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93050932A RU2109513C1 (en) 1993-11-09 1993-11-09 Method to treat atopic dermatitis

Country Status (1)

Country Link
RU (1) RU2109513C1 (en)

Similar Documents

Publication Publication Date Title
ES2137948T3 (en) ADVANCED SYSTEM OF ADMINISTRATION OF MEDICINES AND METHOD OF TREATMENT OF PSYCHIATRIC, NEUROLOGICAL AND OTHER DISORDERS WITH CARBAMACEPINE.
CA2601715A1 (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
EA200000468A1 (en) THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY
RU2001116077A (en) A method for the treatment of cerebral ischemia, as well as the use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischemia
Petersen et al. Chronic pain treatment with intravenous lidocaine
ATE411039T1 (en) USE OF THROMBOPOIETIN AS A MEDICATION FOR THE THERAPY AND PREVENTION OF THROMBOCYTOPENIA
Letechipı́a-Vallejo et al. Neuroprotective effect of melatonin on brain damage induced by acute global cerebral ischemia in cats
Weiss et al. Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512)
Rantz et al. The absorption and excretion of penicillin following continuous intravenous and subcutaneous administration
JP2002530353A5 (en)
Konturek Comparison of pancreatic responses to natural and synthetic secretins in conscious cats
RU93050932A (en) MEANS FOR TREATMENT OF ATOPIC DERMATITIS
RU2000101091A (en) METHOD FOR TREATING DYSTROPHIC DISEASES OF THE RETAIL AND VISUAL NERVE
KR920021152A (en) Anti-neurotoxic activity of the methyl ester of GM_VII ganglioside and its therapeutic use
Belcher et al. 4‐Hydroxyanisole: human pharmacokinetics
Riviello Jr et al. Timing of maintenance phenytoin therapy after intravenous loading dose
SU82331A1 (en) Method of treating cattle theileriosis
US4885288A (en) Pharmaceutical compositions containing lysine acetylsalicylate
Kulkarni et al. Psychotic symptoms resulting from intraventricular infusion of dopamine in Parkinson's disease.
SU1674846A1 (en) Method for treatment lumbosacral radiculitis
RU95113855A (en) METHOD FOR CONSERVATIVE TREATMENT OF EYE BURNS
RU93039118A (en) METHOD OF TREATMENT OF THE SYNDROME OF STENOCARDIA IN ISCHEMIC HEART DISEASE
EP0582932A1 (en) Therapeutic system for the parenteral administration of hematopoietic growth factors
EP0582933A1 (en) Therapeutic system for the parenteral administration of hematopoietic growth factors
RU94023600A (en) METHOD FOR TREATING HEMOCHROMATOSIS